Dr. Richardson - Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Resultsof a Phase 1/2 Study.
Paul Richardson, MD Jerome Lipper Myeloma Center Dana Farber Cancer Institute Boston, MA Member, IMF Board of Scientific Advisors
back
print
related articles
Be the first to comment